New Treatment for Male Hair Loss
Part of Skin clinical trials.
This study tests a new medication called APSMNF to treat male pattern baldness (androgenetic alopecia). The trial will measure how well it works and how safe it is for men experiencing hair loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man between 18 and 60 years old
- You have been diagnosed with male pattern baldness (androgenetic alopecia)
- You are willing to use contraception throughout the study period
- You have no history of severe allergic reactions to the study medication
- You do not have other types of hair loss conditions like alopecia areata or scalp infections
- Your scalp is free of severe inflammation, active infections, or other significant skin conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether a specific hair lotion works and is safe for men with male pattern hair loss. It also checks that results are consistent while you keep similar hair care and avoid certain other hair-loss treatments.
This trial tests a cosmetic anti-hair loss product in men with early to moderate male pattern baldness. It looks at how well the product works and if it can help slow or reduce hair loss.
This trial tests a new treatment for male pattern baldness (androgenic alopecia). It is for men with a moderate level of hair loss who have not used any hair loss treatments in the last 90 days.
This trial tests a new medication called ABS-201 for hair loss. It will first see if the medicine is safe in healthy people, then test if it helps those with male or female pattern baldness.
This study tests whether microneedling, a procedure that uses tiny needles to stimulate the scalp, can help treat male pattern baldness. It may help regrow hair in men with moderate to advanced hair loss.
This study tests an experimental treatment called EPI-001 for androgenetic alopecia—the most common type of hair loss affecting men and women. Researchers will measure how well it works by tracking hair growth over time using special photography and scalp analysis.
Hear when a new Alopecia, Androgenetic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.